Mindie H. Nguyen, MD, MAS, of Stanford Health Care speaks about the publication of the ENCORE data in Hepatology Communications, demonstrating the superior performance of HelioLiver for early detection of liver cancer.
Mindie H. Nguyen, MD, MAS, Fellow AGAF, Fellow FAASLD, is a hepatologist and transplant hepatologist, Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health at Stanford Health Care.
The goal of this study is to define the performance characteristics (sensitivity and specificity) of the HelioLiver test in a study population of subjects with liver cancer at various stages (I to IV) and for control subjects who have been confirmed to be cancer-free by at least one imaging technique, such as ultrasound, MRI, or CT. Individuals who are at high risk for liver cancer and have been advised to undergo liver cancer surveillance will serve as control subjects, as will patients with non-HCC malignancies to determine analytical specificity.
Watch the interview on OncologyTube →
View source version on oncologytube.com.